SCHEMBL19690280

SCHEMBL19690280

CC(C)(c1cccc(Br)c1)N1CCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 3/20 0.40
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
SLC6A2 P23975 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRND Q07001 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
GAA P10253 1/20 0.37
SIGMAR1 Q99720 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13653551 0.98 CYP2B6 (0.62) CYP2B6SMN1; SMN2TDP1HPGDCHRNA1
SCHEMBL3382510 0.85 CYP2B6 (0.42) CYP2B6SMN1; SMN2CA1CA2CA5A
SCHEMBL19710841 0.80 CYP2B6 (0.61) CYP2B6HPGDCHRNA1CHRNGCHRNB1
SCHEMBL1240328 0.78 CHRM3 (0.47) CYP2B6SMN1; SMN2HPGDCHRNA1CHRNG
SCHEMBL13653764 0.77 CYP2B6 (0.62) CYP2B6GAASIGMAR1ALDH1A1MAPK1
SCHEMBL2297308 0.77 CYP2B6 (0.62) CYP2B6SMN1; SMN2HPGDGAASIGMAR1
SCHEMBL19011533 0.77 CYP2B6 (0.96) CYP2B6SMN1; SMN2SLC6A2SLC6A3SIGMAR1
SCHEMBL19701986 0.76 CYP2B6 (0.56) CYP2B6SMN1; SMN2TDP1HPGDCA1
SCHEMBL12665881 0.76 CYP2B6 (0.66) CYP2B6SMN1; SMN2HPGDGAASIGMAR1
SCHEMBL2697745 0.75 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3SIGMAR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS PIK3R3, JAK2, JAK3 CYP2B6 1568/4885SMN1; SMN2 4355/4885TDP1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.